DiaMonTech AG is a technology company.
DiaMonTech AG has raised $6.0M across 1 funding round.
DiaMonTech AG has raised $6.0M in total across 1 funding round.
DiaMonTech AG has raised $6.0M in total across 1 funding round.
DiaMonTech AG's investors include IBB Ventures.
DiaMonTech AG is a Berlin-based medical technology company developing non-invasive blood glucose monitoring devices using patented mid-infrared laser-based photothermal detection technology, eliminating the need for finger pricks, blood, or test strips.[1][2][4] It targets over 400 million people worldwide with diabetes, primarily Type 2 patients requiring frequent monitoring to prevent complications like cardiovascular disease and kidney failure, while also appealing to non-diabetics for preventive health tracking.[2][4][5] The company offers products like D-BASE (a shoebox-sized desktop device for clinical trials, CE-certified in 2019), D-Pocket (a portable pocket-sized monitor that won the 2023 Healthcare Innovation World Cup), and D-SENSOR (a wearable in development for continuous real-time monitoring).[1][3][5] Growth momentum includes a €12 million funding round from investors like Samsung Next and Companisto to accelerate miniaturization, plus awards such as the 2024 Health-i Award and Deep Tech Berlin Award.[3]
DiaMonTech AG was founded in 2015 in Berlin, Germany, spinning out from over 20 years of research at Goethe University Frankfurt on infrared spectroscopy for glucose detection.[1][2][4] The core innovation emerged from this academic foundation, leading to the patented mid-infrared photothermal deflection spectroscopy (MIR-PTD) technology, validated in a clinical study by the Institute for Diabetes Technology in Ulm comparing it to invasive methods across 100 volunteers.[3][4] Early traction came with CE certification for the D-BASE device in 2019, confirming safety and performance standards, followed by pivotal wins like the 2023 Healthcare Innovation World Cup for D-Pocket and recent €12 million funding to push toward consumer wearables.[3]
DiaMonTech rides the non-invasive diabetes management wave, addressing a €61 million+ European diabetes burden where poor monitoring adherence drives complications and healthcare strain.[4] Timing aligns with medtech miniaturization trends—quantum cascade lasers and photonics enabling smartphone-sized devices—fueled by rising Type 2 diabetes prevalence and demand for wearable health tech like continuous glucose monitors (CGMs).[2][5] Market forces favor it: regulatory nods like CE marking, clinical validation, and funding from deep tech investors position it against incumbents reliant on invasives; it influences Europe's healthtech ecosystem by promoting sustainable, patient-centered innovation and job creation in biotech.[3][4][6]
DiaMonTech is poised to launch consumer wearables like D-SENSOR, leveraging €12 million funding for rapid miniaturization and global scaling, potentially transforming diabetes care for millions.[3][5] Trends like AI-integrated wearables, preventive health for non-diabetics, and photonics advancements will propel it, with partnerships (e.g., Samsung) amplifying reach.[2][3] Its influence may evolve from niche innovator to market leader, easing healthcare burdens if regulatory expansions (e.g., FDA) follow EU success—redefining glucose monitoring as effortless as checking a smartwatch. This builds on its laser-precision origins, delivering the pain-free future promised since 2015.[1][2]
DiaMonTech AG has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Venture Round in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $6.0M Venture Round | IBB Ventures |